Anthrax Contract Better Positions Pfenex In Biodefense
This article was originally published in Scrip
Executive Summary
An anthrax vaccine contract with the US federal government, which eventually could be worth $143.5m, has better positioned Pfenex in the lucrative biodefense arena with other players, like Emergent Biosolutions.